Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)
Latest Information Update: 05 Apr 2022
At a glance
- Drugs Cenicriviroc (Primary)
- Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Tobira Therapeutics
- 03 Apr 2022 This trial has been completed in Italy (Date of the global end of the trial : 05-Jan-2022), according to European Clinical Trials Database record.
- 28 Jul 2021 This trial has been completed in Germany, according to European Clinical Trials Database.
- 16 May 2021 This trial has been completed in Belgium, according to European Clinical Trials Database.